Quick Answer
Royalty Pharma plc reported Stockholders Equity of $9.71 billion for fiscal year 2025.
Royalty Pharma plc Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $9.71B | -6.1% |
| 2024 | $10.34B | +2.6% |
| 2023 | $10.08B | +5.9% |
| 2022 | $9.53B | -7.1% |
| 2021 | $10.25B | +3.6% |
| 2020 | $9.90B | +61.1% |
| 2019 | $6.14B | +34.9% |
| 2018 | $4.55B | +2.1% |
| 2017 | $4.46B | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $9.62B | -6.2% | +1.2% |
| June 30, 2025 | $9.50B | -2.6% | -2.9% |
| March 31, 2025 | $9.79B | -0.8% | -5.4% |
| December 31, 2024 | $10.34B | +2.6% | +0.8% |
| September 30, 2024 | $10.26B | +7.0% | +5.2% |
| June 30, 2024 | $9.75B | -0.6% | -1.1% |
| March 31, 2024 | $9.86B | +0.4% | -2.2% |
| December 31, 2023 | $10.08B | +5.9% | +5.2% |
- Royalty Pharma plc showed a decrease of -6.1% in Stockholders Equity compared to the prior fiscal year.
- Over the 2017–2025 period, Royalty Pharma plc’s stockholders equity has grown by 117.8% (from $4.46 billion to $9.71 billion).
- The most recent figure is from Royalty Pharma plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: